Analysis Tools
normal phenotype
|
• authors state that Krt19 is non-essential for viability; homozygous Krt19 animals carrying the R26-YFP reporter are used for lineage tracing, indicating that homozygotes are viable
|
|
Allele Symbol Allele Name Allele ID |
Krt19tm1(cre/ERT)Ggu targeted mutation 1, Guoqiang Gu MGI:3797107 |
||||||||||||||||||||||||
| Summary |
5 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• authors state that Krt19 is non-essential for viability; homozygous Krt19 animals carrying the R26-YFP reporter are used for lineage tracing, indicating that homozygotes are viable
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 13 days after tamoxifen injection, a greater proportion of insulin-immunostaining duct cells are observed in pancreas sections from 6-9 week old mice bearing both the conditional Neurog3 knock-in and a pancreatic duct-specific cre recombinase/estrogen receptor fusion knock-in allele than in sections from control mice with only the conditional allele (highly significant at p = 0.0042 (<= 0.01) by Student's unpaired t test).
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• tamoxifen treated mice die within 2 months from intestinal cancers before developing skin tumors
|
|
• tamoxifen treated mice develop intestinal cancers
|
|
• tamoxifen treated mice develop intestinal cancers
|
|
• when back skin from mutant animals is grafted onto back skin of nude mice, all engrafted mice develop skin tumors, including ulcerative lesions (benign and squamous cell carcinomas) within 2 months of tamoxifen administration
|
|
• tamoxifen treated mice develop terminal intestinal carcinomas with 2 months of treatment
|
|
• when back skin from mutant animals is grafted onto back skin of nude mice, all engrafted mice develop skin tumors, including ulcerative lesions (benign and squamous cell carcinomas) within 2 months of tamoxifen administration
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice administered tamoxifen at 8 weeks of age show a median survival of 30 days after tamoxifen injection
|
|
• colonic serrated epithelial changes in tamoxifen treated mice
|
|
• hyperplastic changes of gastric mucosa in tamoxifen treated mice
|
|
• extrahepatic bile duct is rigid and dilated in tamoxifen treated mice
• papillary hyperplasia of the extrahepatic biliary tract
|
|
• papillary hyperplasia of the gallbladder in tamoxifen treated mice
|
|
• gallbladder and cystic duct are rigid and dilated in tamoxifen treated mice
|
|
• in tamoxifen treated mice
|
|
• PanIN-like lesions and hyperplasia in the pancreatic ducts in tamoxifen treated mice
• however, no obvious tumors are seen in mice administered tamoxifen at 8 weeks of age
|
|
• obstructive pneumonia in tamoxifen treated mice
|
|
• extrahepatic bile duct is rigid and dilated in tamoxifen treated mice
• papillary hyperplasia of the extrahepatic biliary tract
|
|
• papillary hyperplasia of the gallbladder in tamoxifen treated mice
|
|
• gallbladder and cystic duct are rigid and dilated in tamoxifen treated mice
|
|
• in tamoxifen treated mice
|
|
• liver of tamoxifen treated mice shows pre-malignant papillary ductal lesions in periportal areas
|
|
• PanIN-like lesions and hyperplasia in the pancreatic ducts in tamoxifen treated mice
• however, no obvious tumors are seen in mice administered tamoxifen at 8 weeks of age
|
|
• obstructive pneumonia in tamoxifen treated mice
|
|
• papillary hyperplasia of bronchial epithelia in tamoxifen treated mice
|
|
• respiratory failure by lung lesions in tamoxifen treated mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 2-4 months after tamoxifen treatment, lip tumors develop in 78% of treated mice
|
|
• 2-4 months after tamoxifen treatment, tumors develop in the back skin in 33% of treated mice
|
|
• skin tumors are benign papillomas with no sign of malignant transformation seen up to 4 months after treatment with tamoxifen
|
|
• 2-4 months after tamoxifen treatment, lip tumors develop in 78% of treated mice
|
|
• 2-4 months after tamoxifen treatment, lip tumors develop in 78% of treated mice
|
|
• sebaceous cyst formation is observed as result of bulge stem cell proliferation and abnormal hair follicle (HF) differentiation
|
|
• 1 month after tamoxifen treatment, Kras activation results in the enlargement of the majority of sebaceous glands
|
|
• 1 month after tamoxifen treatment, Kras activation results in transient increase in hair follicle bulge stem cell (SC) proliferation
• hyperproliferative bulge SCs can still undergo terminal differentiation
|
|
• 2-4 months after tamoxifen treatment, tumors develop in the back skin in 33% of treated mice
|
|
• skin tumors are benign papillomas with no sign of malignant transformation seen up to 4 months after treatment with tamoxifen
|
|
• sebaceous cyst formation is observed as result of bulge stem cell proliferation and abnormal hair follicle (HF) differentiation
|
|
• 1 month after tamoxifen treatment, Kras activation results in the enlargement of the majority of sebaceous glands
|
|
• 1 month after tamoxifen treatment, Kras activation results in transient increase in hair follicle bulge stem cell (SC) proliferation
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/09/2024 MGI 6.23 |
|
|
|
||